Should you invest in... the biotech business?

IF YOU are an investor looking for a "frontier market", you do not have to stray far from home. For those research-based companies at the cutting edge of technological development will give you a rollercoaster ride for your money every bit as exciting, and fraught with risk, as any emerging market.

Chief among these high- risk enterprises are the biotechnology stocks, those companies whose raison d'etre is to develop new products and processes through biochemical research and whose success or failure is often dependent upon their ability to develop and market a single new drug.

"There are very few biotech stocks that we look at, because the companies are so tiny and it has been an awful subsector to be in," says Jeremy Batstone of NatWest Stockbrokers. "It is an unloved sector which has seen a lot of disappointments, the most high profile of which was British Biotech."

In contrast to the outperformance of their bigger counterparts in the pharmaceutical companies, the small biotech sector has been suffering. Mark Mathias, marketing director of Finsbury Asset management,says: "Biotech shares have been complete dogs for two years. There have been some celebrated cases of bad management, which led to a bad press for the sector, which has depressed sentiment."

Glenn Meyer of Pavilion Asset Management says: "You have to adopt a portfolio approach to the biotech sector. Investing in individual biotech companies should be left to the specialists."

Lesley Buckett of Hill Samuel Asset Management says: "They are mainly very small cap stocks. The private investor would have to buy a lot of them to make an impact and the best way would be to have a portfolio via something like an investment trust. People who specialise in looking only at these stocks get it wrong, so what chance does the individual have? You are dealing with `blue sky' research, and how do you know that these scientists are actually going to come up with anything?"

Jeremy Batstone adds: "The trouble with biotech stocks is that they have had their glory days. Two or three years ago, when British Biotech's `wonder drug' was starting trials, these stocks were racing away and standing on ridiculous multiples. But as they have no earnings you can't properly rate companies like that - British Biotech was almost in the FTSE 100 at one point and hadn't actually produced anything. Now you can really see the wood for the trees and there isn't much of either."

Lesley Buckett says: "Biotech stocks were very lowly rated, then got very highly rated very quickly, as things like British Biotech began to take off. The pharmaceutical sector is a large part of the market, but that is on the basis of three very large stocks. The biotech companies have become even smaller with the derating they have experienced over the past couple of years."

Much of the problems associated with the sector have stemmed from long lead time. Mark Mathias says: "The underlying businesses take cash at the outset, then there is a long period when nothing seems to be happening because they are in the laboratory coming up with the drugs. So there was no news coming out of the biotechs, then bad news because of British Biotech and other bad management situations. Now positive news is coming through."

Jeremy Batstone says: "A company will build up market expectation of finding a cure for cancer or whatever, then let you down in a big way when you find it doesn't work. It means taking giant leaps of faith." Lesley Buckett says: "Ratings have become more sensible and you are beginning to see the same sort of cycle you see in the US. But these companies burn cash at an enormous rate. They will all need refinancing at some point."

When it does work, the rewards can be enormous and the best evidence comes from America. Mathias adds: "Biotech companies make profits by doing deals. There are 21 biotech companies in the US representing a total of $1.5bn (pounds 940m) in profits and this figures is going to rise to $2.5bn by the end of 2000. And they are available on an average p/e of 25 times earnings, which is reasonable.Some companies, like Powderject Pharmaceuticals, have developed world-leading technologies, although in this case it is a delivery system rather than an actual drug. SkyePharma is a company with successful technology, as is Chiroscience."

Jeremy Batstone says: "You have to consider how they are going to sell these drugs. Have they got marketing power? Chiroscience had a deal with Zeneca to market a drug, then after the Zeneca-Astra dealChiroscience was out in the cold, because Astra had a similar drug and didn't want a third party involved."

Start your day with The Independent, sign up for daily news emails
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Software Engineer / Software Developer

£40-50K: Guru Careers: We are seeking an experienced Software Engineer / Softw...

Ashdown Group: Trainee Consultant - Surrey/ South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Ashdown Group: Trainee Consultant - Surrey / South West London

£22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

Recruitment Genius: Claims Administrator

£16000 - £18500 per annum: Recruitment Genius: This is an excellent opportunit...

Day In a Page

Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

Fishing is on Nigel Farage's mind

Ukip leader casts a line to the disaffected
Who is bombing whom in the Middle East? It's amazing they don't all hit each other

Who is bombing whom in the Middle East?

Robert Fisk untangles the countries and factions
China's influence on fashion: At the top of the game both creatively and commercially

China's influence on fashion

At the top of the game both creatively and commercially
Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

The man known as GOD has a reputation for getting the job done

Lord O'Donnell's three principles of rule
Rainbow shades: It's all bright on the night

Rainbow shades

It's all bright on the night
'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

Bread from heaven

Dutch survivors thank RAF for World War II drop that saved millions
Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

How 'the Axe' helped Labour

UK will be 'run for the wealthy and powerful' if Tories retain power
Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

The price to be paid for challenging the rule of extremists

A revolution now 'consuming its own children'
Welcome to the world of Megagames

Welcome to the world of Megagames

300 players take part in Watch the Skies! board game in London
'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

Charlotte Gainsbourg on 'Nymphomaniac'

Starring in one of the most explicit films ever
Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

Robert Fisk in Abu Dhabi

The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

Vince Cable exclusive interview

Charging fees for employment tribunals was 'a very bad move'
Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

Iwan Rheon is returning to his Welsh roots

Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

It's time for my close-up

Meet the man who films great whites for a living
Increasing numbers of homeless people in America keep their mobile phones on the streets

Homeless people keep mobile phones

A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before